Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 2/20 | 0.33 |
| ▸ | ALPI | P09923 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP7 | P09237 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
| ▸ | MMP14 | P50281 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19013712 | 0.70 | ALDH1A1 (0.33) | — | |
| SCHEMBL28756737 | 0.67 | HTT (0.39) | ALPLALPICA12CA2 | |
| SCHEMBL22367351 | 0.66 | — | — | |
| SCHEMBL17825204 | 0.66 | GABRA1 (0.32) | MMP9 | |
| SCHEMBL28621046 | 0.64 | — | — | |
| SCHEMBL27727965 | 0.63 | POLB (0.39) | CA12CA2MMP2MMP7MMP9 | |
| SCHEMBL17198498 | 0.63 | — | — | |
| SCHEMBL27715687 | 0.62 | PSMB8 (0.38) | — | |
| SCHEMBL27737035 | 0.62 | UHRF1 (0.41) | ALPLALPICA12CA2MMP2 | |
| SCHEMBL27286890 | 0.62 | CA12 (0.40) | ALPLALPICA12CA2MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11242344-B2 | (4-hydroxypyrrolidin-2-yl)-heterocyclic compounds and methods of use thereof | GENENTECH, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| US-20210309660-A1 | (4-HYDROXYPYRROLIDIN-2-YL)-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH INC (US) | 2021-10-07 | — | — | US | disclosed |
| EP-3700901-A1 | (4-HYDROXYPYRROLIDIN-2-YL)-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | Genentech, Inc. (US) | 2020-09-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210309660-A1 | (4-HYDROXYPYRROLIDIN-2-YL)-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | VHL, MDM2, CUL2 | ALPL 3648/4885ALPI 4397/4885CA12 3584/4885 |
| US-11242344-B2 | (4-hydroxypyrrolidin-2-yl)-heterocyclic compounds and methods of use thereof | VHL, MDM2, CUL2 | ALPL 3648/4885ALPI 4397/4885CA12 3584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.